Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma
The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New modalities using targeted therapy based on new information in molecular biology and immunology hold promise for better outcomes with less toxicity. We review data on the use of ra...
Gespeichert in:
| Veröffentlicht in: | Seminars in oncology 2002-02, Vol.29 (1), p.87-92 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 92 |
|---|---|
| container_issue | 1 |
| container_start_page | 87 |
| container_title | Seminars in oncology |
| container_volume | 29 |
| creator | Gordon, Leo I Witzig, Thomas E Wiseman, Greg A Flinn, Ian W Spies, Stewart S Silverman, Daniel H Emmanuolides, Christos Cripe, Larry Saleh, Mansoor Czuczman, Myron S Olejnik, Teresa White, Christine A Grillo-López, Antonio J |
| description | The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New modalities using targeted therapy based on new information in molecular biology and immunology hold promise for better outcomes with less toxicity. We review data on the use of radiolabeled monoclonal antibodies directed against the CD20 antigen on malignant B cells. We discuss the major radionuclides available, iodine 131 (131I), tositumomab, and yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA) and present data on new approaches in labeling antibodies that have facilitated their use. Clinical trial data with the yttrium-labeled antibodies are discussed. The use of dosimetry as a means for predicting toxicity is discussed, and the questions of long-term toxicity (late effects) are addressed. These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise. Semin Oncol 29 (suppl 2):87-92. Copyright © 2002 by W.B. Saunders Company. |
| doi_str_mv | 10.1053/sonc.2002.30148 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1863221795</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0093775402500828</els_id><sourcerecordid>1863221795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c291t-4710d23b02bd97e4c6faf5e42bcba1158fb917d2e21cdb8f3996748e416db3d33</originalsourceid><addsrcrecordid>eNp1kDtvFDEUhS0EIkugpkPuoJmNX7MzLlEUEqRINKRIZflxJzGM7cH2APvv482uREV1b_GdI50PofeUbCnp-UVJ0W4ZIWzLCRXjC7ShPWfdOJDxJdoQInk3DL04Q29K-dEwOjD2Gp1ROgrGpdigeF9r9mvAkmBvsq9rSEEbXP36F6qOOGvnkw9hjak-QtbLHk8p4wyzXgo4_PxPWdua8h7P6U_30CKAY4rdTXIPP338WPC8D8tjK36LXk16LvDudM_R3Zer75c33e2366-Xn287yyStnRgocYwbwoyTAwi7m_TUg2DGGk1pP05G0sExYNQ6M05cyt0gRhB05wx3nJ-jT8feJadfK5Sqgi8W5llHSGtRdNxx1mzIvqEXR9TmVErbopbsg857RYk6SFYHyeogWT1LbokPp_LVBHD_-JPVBsgjAG3ibw9ZFeshWnA-g63KJf_f8icS3I4a</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1863221795</pqid></control><display><type>article</type><title>Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Gordon, Leo I ; Witzig, Thomas E ; Wiseman, Greg A ; Flinn, Ian W ; Spies, Stewart S ; Silverman, Daniel H ; Emmanuolides, Christos ; Cripe, Larry ; Saleh, Mansoor ; Czuczman, Myron S ; Olejnik, Teresa ; White, Christine A ; Grillo-López, Antonio J</creator><creatorcontrib>Gordon, Leo I ; Witzig, Thomas E ; Wiseman, Greg A ; Flinn, Ian W ; Spies, Stewart S ; Silverman, Daniel H ; Emmanuolides, Christos ; Cripe, Larry ; Saleh, Mansoor ; Czuczman, Myron S ; Olejnik, Teresa ; White, Christine A ; Grillo-López, Antonio J</creatorcontrib><description>The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New modalities using targeted therapy based on new information in molecular biology and immunology hold promise for better outcomes with less toxicity. We review data on the use of radiolabeled monoclonal antibodies directed against the CD20 antigen on malignant B cells. We discuss the major radionuclides available, iodine 131 (131I), tositumomab, and yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA) and present data on new approaches in labeling antibodies that have facilitated their use. Clinical trial data with the yttrium-labeled antibodies are discussed. The use of dosimetry as a means for predicting toxicity is discussed, and the questions of long-term toxicity (late effects) are addressed. These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise. Semin Oncol 29 (suppl 2):87-92. Copyright © 2002 by W.B. Saunders Company.</description><identifier>ISSN: 0093-7754</identifier><identifier>EISSN: 1532-8708</identifier><identifier>DOI: 10.1053/sonc.2002.30148</identifier><identifier>PMID: 11842394</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antigens, CD20 ; Clinical Trials as Topic ; Humans ; Iodine Radioisotopes - therapeutic use ; Lymphoma, B-Cell - radiotherapy ; Lymphoma, Non-Hodgkin - radiotherapy ; Quality of Life ; Radioimmunotherapy ; Radiopharmaceuticals - therapeutic use ; Radiotherapy Dosage ; Yttrium Radioisotopes - therapeutic use</subject><ispartof>Seminars in oncology, 2002-02, Vol.29 (1), p.87-92</ispartof><rights>2002 W.B. Saunders Company</rights><rights>Copyright 2002 by W.B. Saunders Company.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c291t-4710d23b02bd97e4c6faf5e42bcba1158fb917d2e21cdb8f3996748e416db3d33</citedby><cites>FETCH-LOGICAL-c291t-4710d23b02bd97e4c6faf5e42bcba1158fb917d2e21cdb8f3996748e416db3d33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0093775402500828$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11842394$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gordon, Leo I</creatorcontrib><creatorcontrib>Witzig, Thomas E</creatorcontrib><creatorcontrib>Wiseman, Greg A</creatorcontrib><creatorcontrib>Flinn, Ian W</creatorcontrib><creatorcontrib>Spies, Stewart S</creatorcontrib><creatorcontrib>Silverman, Daniel H</creatorcontrib><creatorcontrib>Emmanuolides, Christos</creatorcontrib><creatorcontrib>Cripe, Larry</creatorcontrib><creatorcontrib>Saleh, Mansoor</creatorcontrib><creatorcontrib>Czuczman, Myron S</creatorcontrib><creatorcontrib>Olejnik, Teresa</creatorcontrib><creatorcontrib>White, Christine A</creatorcontrib><creatorcontrib>Grillo-López, Antonio J</creatorcontrib><title>Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma</title><title>Seminars in oncology</title><addtitle>Semin Oncol</addtitle><description>The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New modalities using targeted therapy based on new information in molecular biology and immunology hold promise for better outcomes with less toxicity. We review data on the use of radiolabeled monoclonal antibodies directed against the CD20 antigen on malignant B cells. We discuss the major radionuclides available, iodine 131 (131I), tositumomab, and yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA) and present data on new approaches in labeling antibodies that have facilitated their use. Clinical trial data with the yttrium-labeled antibodies are discussed. The use of dosimetry as a means for predicting toxicity is discussed, and the questions of long-term toxicity (late effects) are addressed. These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise. Semin Oncol 29 (suppl 2):87-92. Copyright © 2002 by W.B. Saunders Company.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antigens, CD20</subject><subject>Clinical Trials as Topic</subject><subject>Humans</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Lymphoma, B-Cell - radiotherapy</subject><subject>Lymphoma, Non-Hodgkin - radiotherapy</subject><subject>Quality of Life</subject><subject>Radioimmunotherapy</subject><subject>Radiopharmaceuticals - therapeutic use</subject><subject>Radiotherapy Dosage</subject><subject>Yttrium Radioisotopes - therapeutic use</subject><issn>0093-7754</issn><issn>1532-8708</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kDtvFDEUhS0EIkugpkPuoJmNX7MzLlEUEqRINKRIZflxJzGM7cH2APvv482uREV1b_GdI50PofeUbCnp-UVJ0W4ZIWzLCRXjC7ShPWfdOJDxJdoQInk3DL04Q29K-dEwOjD2Gp1ROgrGpdigeF9r9mvAkmBvsq9rSEEbXP36F6qOOGvnkw9hjak-QtbLHk8p4wyzXgo4_PxPWdua8h7P6U_30CKAY4rdTXIPP338WPC8D8tjK36LXk16LvDudM_R3Zer75c33e2366-Xn287yyStnRgocYwbwoyTAwi7m_TUg2DGGk1pP05G0sExYNQ6M05cyt0gRhB05wx3nJ-jT8feJadfK5Sqgi8W5llHSGtRdNxx1mzIvqEXR9TmVErbopbsg857RYk6SFYHyeogWT1LbokPp_LVBHD_-JPVBsgjAG3ibw9ZFeshWnA-g63KJf_f8icS3I4a</recordid><startdate>200202</startdate><enddate>200202</enddate><creator>Gordon, Leo I</creator><creator>Witzig, Thomas E</creator><creator>Wiseman, Greg A</creator><creator>Flinn, Ian W</creator><creator>Spies, Stewart S</creator><creator>Silverman, Daniel H</creator><creator>Emmanuolides, Christos</creator><creator>Cripe, Larry</creator><creator>Saleh, Mansoor</creator><creator>Czuczman, Myron S</creator><creator>Olejnik, Teresa</creator><creator>White, Christine A</creator><creator>Grillo-López, Antonio J</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200202</creationdate><title>Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma</title><author>Gordon, Leo I ; Witzig, Thomas E ; Wiseman, Greg A ; Flinn, Ian W ; Spies, Stewart S ; Silverman, Daniel H ; Emmanuolides, Christos ; Cripe, Larry ; Saleh, Mansoor ; Czuczman, Myron S ; Olejnik, Teresa ; White, Christine A ; Grillo-López, Antonio J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c291t-4710d23b02bd97e4c6faf5e42bcba1158fb917d2e21cdb8f3996748e416db3d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antigens, CD20</topic><topic>Clinical Trials as Topic</topic><topic>Humans</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Lymphoma, B-Cell - radiotherapy</topic><topic>Lymphoma, Non-Hodgkin - radiotherapy</topic><topic>Quality of Life</topic><topic>Radioimmunotherapy</topic><topic>Radiopharmaceuticals - therapeutic use</topic><topic>Radiotherapy Dosage</topic><topic>Yttrium Radioisotopes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gordon, Leo I</creatorcontrib><creatorcontrib>Witzig, Thomas E</creatorcontrib><creatorcontrib>Wiseman, Greg A</creatorcontrib><creatorcontrib>Flinn, Ian W</creatorcontrib><creatorcontrib>Spies, Stewart S</creatorcontrib><creatorcontrib>Silverman, Daniel H</creatorcontrib><creatorcontrib>Emmanuolides, Christos</creatorcontrib><creatorcontrib>Cripe, Larry</creatorcontrib><creatorcontrib>Saleh, Mansoor</creatorcontrib><creatorcontrib>Czuczman, Myron S</creatorcontrib><creatorcontrib>Olejnik, Teresa</creatorcontrib><creatorcontrib>White, Christine A</creatorcontrib><creatorcontrib>Grillo-López, Antonio J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gordon, Leo I</au><au>Witzig, Thomas E</au><au>Wiseman, Greg A</au><au>Flinn, Ian W</au><au>Spies, Stewart S</au><au>Silverman, Daniel H</au><au>Emmanuolides, Christos</au><au>Cripe, Larry</au><au>Saleh, Mansoor</au><au>Czuczman, Myron S</au><au>Olejnik, Teresa</au><au>White, Christine A</au><au>Grillo-López, Antonio J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma</atitle><jtitle>Seminars in oncology</jtitle><addtitle>Semin Oncol</addtitle><date>2002-02</date><risdate>2002</risdate><volume>29</volume><issue>1</issue><spage>87</spage><epage>92</epage><pages>87-92</pages><issn>0093-7754</issn><eissn>1532-8708</eissn><abstract>The treatment of malignant lymphoma has improved over the past 20 years, but the majority of patients are not cured. New modalities using targeted therapy based on new information in molecular biology and immunology hold promise for better outcomes with less toxicity. We review data on the use of radiolabeled monoclonal antibodies directed against the CD20 antigen on malignant B cells. We discuss the major radionuclides available, iodine 131 (131I), tositumomab, and yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin; IDEC Pharmaceuticals, San Diego, CA) and present data on new approaches in labeling antibodies that have facilitated their use. Clinical trial data with the yttrium-labeled antibodies are discussed. The use of dosimetry as a means for predicting toxicity is discussed, and the questions of long-term toxicity (late effects) are addressed. These targeted approaches to the treatment of malignancy, and lymphoma in particular, hold great promise. Semin Oncol 29 (suppl 2):87-92. Copyright © 2002 by W.B. Saunders Company.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>11842394</pmid><doi>10.1053/sonc.2002.30148</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0093-7754 |
| ispartof | Seminars in oncology, 2002-02, Vol.29 (1), p.87-92 |
| issn | 0093-7754 1532-8708 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1863221795 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antibodies, Monoclonal - therapeutic use Antigens, CD20 Clinical Trials as Topic Humans Iodine Radioisotopes - therapeutic use Lymphoma, B-Cell - radiotherapy Lymphoma, Non-Hodgkin - radiotherapy Quality of Life Radioimmunotherapy Radiopharmaceuticals - therapeutic use Radiotherapy Dosage Yttrium Radioisotopes - therapeutic use |
| title | Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T01%3A22%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Yttrium%2090%20ibritumomab%20tiuxetan%20radioimmunotherapy%20for%20relapsed%20or%20refractory%20low-grade%20non-Hodgkin's%20lymphoma&rft.jtitle=Seminars%20in%20oncology&rft.au=Gordon,%20Leo%20I&rft.date=2002-02&rft.volume=29&rft.issue=1&rft.spage=87&rft.epage=92&rft.pages=87-92&rft.issn=0093-7754&rft.eissn=1532-8708&rft_id=info:doi/10.1053/sonc.2002.30148&rft_dat=%3Cproquest_cross%3E1863221795%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1863221795&rft_id=info:pmid/11842394&rft_els_id=S0093775402500828&rfr_iscdi=true |